Literature DB >> 14668642

Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes.

Robert McMillan1.   

Abstract

Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by thrombocytopenia due to autoantibody-induced platelet destruction. The majority of these autoantibodies are directed to epitopes on either glycoprotein (GP) IIb-IIIa or GPIb-IX. The newer antigen-specific autoantibody assays are capable of detecting both platelet-associated and plasma autoantibodies and have a definite role in the diagnosis of immune thrombocytopenia. A positive assay provides strong evidence for the presence of immune thrombocytopenia both in chronic ITP and in other diseases where immune thrombocytopenia may occur, such as collagen vascular disease and lymphoproliferative disorders. However, a negative assay does not rule out the presence of ITP. Somewhat concerning is the large number of patients who have negative assays. Several possible explanations for these observations are discussed. Recent studies have localized some ITP autoepitopes to specific regions of GPIIb-IIIa and GPIb-IX. Most autoepitopes on GPIIb-IIIa are conformational, in view of their dependence on divalent cations, and are localized to the N-terminal portion of GPIIb, while the GPIb-IX autoepitopes that have been identified are localized to GPIb amino acids 333-341.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668642     DOI: 10.1097/00043426-200312001-00013

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  11 in total

Review 1.  Piecing together the humoral and cellular mechanisms of immune thrombocytopenia.

Authors:  Lisa J Toltl; Ishac Nazi; Reza Jafari; Donald M Arnold
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

Review 2.  Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.

Authors:  Lisa J Toltl; Donald M Arnold
Journal:  Br J Haematol       Date:  2010-11-18       Impact factor: 6.998

3.  Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.

Authors:  Sarah J Barsam; Bethan Psaila; Marc Forestier; Lemke K Page; Peter A Sloane; Julia T Geyer; Glynis O Villarica; Mary M Ruisi; Terry B Gernsheimer; Juerg H Beer; James B Bussel
Journal:  Blood       Date:  2011-03-09       Impact factor: 22.113

4.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

5.  Rapid platelet turnover in WASP(-) mice correlates with increased ex vivo phagocytosis of opsonized WASP(-) platelets.

Authors:  Amanda Prislovsky; Bindumadhav Marathe; Amira Hosni; Alyssa L Bolen; Falk Nimmerjahn; Carl W Jackson; Darryl Weiman; Ted S Strom
Journal:  Exp Hematol       Date:  2008-03-17       Impact factor: 3.084

Review 6.  Immune thrombocytopenia.

Authors:  Gaurav Kistangari; Keith R McCrae
Journal:  Hematol Oncol Clin North Am       Date:  2013-06       Impact factor: 3.722

Review 7.  The thrombocytopenia of WAS: a familial form of ITP?

Authors:  Ted S Strom
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

8.  A Case of HELLP Syndrome in a Patient with Immune Thrombocytopenic Purpura.

Authors:  Sebastián Ben; Fabián Rodríguez; Carlos Severo; Natalia Debat
Journal:  Obstet Gynecol Int       Date:  2010-09-13

9.  B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.

Authors:  Joseph M Tuscano; Jacob Sands
Journal:  Biologics       Date:  2009-07-13

10.  Treatment of immune thrombocytopenic purpura: focus on eltrombopag.

Authors:  Lawrence Rice
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.